Park DG, Jeong WJ, Park JM, et al. - Researchers conducted this prospective, multicenter, noncomparative, open-label clinical trial to assess the functional and anatomical outcomes of a treat-and-extend (TAE) regimen with aflibercept for treatment-naive macular edema (ME) secondary to branch retinal vein occlusion (BRVO). Prior to the TAE regimen, 48 patients' eyes received three monthly intravitreal aflibercept injections. However, if the patient's best-corrected visual acuity was ≥ 20/20 and the central macular thickness was < 250 μm during the loading phase, the TAE regimen was immediately initiated. The TAE regimen with aflibercept for ME secondary to BRVO, with treatment intervals of up to 16 weeks, demonstrated comparable efficacy to the fixed-dosing regimen while having a lower treatment burden.